Vertex Pharmaceuticals: A Look At Their Pain Therapy Program
Vertex Pharmaceuticals is diversifying from its cystic fibrosis dominance into pain and other markets. Check out our ...
Wells Fargo Remains a Hold on Vertex Pharmaceuticals (VRTX)
Wells Fargo analyst Mohit Bansal maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price target ...
Vertex Pharmaceuticals price target raised to $420 from $408 at RBC Capital
RBC Capital raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $420 from $408 and keeps a Sector Perform rating on the shares.
Demystifying Vertex Pharmaceuticals: Insights From 17 Analyst Reviews
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...
TechCrunch20d
Google adds its voice model Chirp 3 to its Vertex AI platform
In the latest development, Google today announced that it would be adding Chirp 3 — its speech-to-text and HD text-to-speech models — to its Vertex AI development platform starting next week.
Yahoo Finance20d
Vertex Up 25% YTD: Should You Buy, Sell or Hold the Stock?
Vertex holds a dominant position in the cystic franchise (“CF”) market. Its CF sales continue to grow, driven by higher sales of Trikafta/Kaftrio in younger age groups. Vertex’s CF product ...
The Motley Fool26d
Where Will Vertex Pharmaceuticals Be in 10 Years?
Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...